Daniel van Wamelen (The Maurice Wohl Clinical Neuroscience Institute, King’s College London, UK) discusses non-motor symptoms in Parkinson’s disease (PD) and the repurposing of existing medication in PD to target new areas such as cognition.
- What are the current unmet needs in the treatment of non-motor symptoms in Parkinson’s disease (PD)? (0:04)
- How important are non-motor symptoms in PD and could you give some examples? (1:49)
- Could you talk a bit about current treatment strategies for non-motor symptoms? (3:09)
View Part 2 of this expert interview here.
Speaker disclosure: Daniel van Wamelen has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Parkinson's Disease
Prof. K Ray Chaudhuri: Sleep Issues in Parkinson’s Disease – Diagnosis, Intervention & Practical Advice
In conjunction with the European Parkinson’s Disease Association (EPDA), we had the pleasure of meeting with Prof. K Ray Chaudhuri to discuss sleep issues among people with Parkinson’s Disease. The discussion highlights the appropriate diagnosis of sleep disorders, intervention strategies, practical advice for healthcare professionals, patients and caregivers, and the impact of sleep issues on […]
Raul Martinez-Fernandez, AAN 2021: Focused Ultrasound Subthalamotomy for Parkinson’s Disease
TouchNEUROLOGY met with Raul Martinez-Fernandez (University Hospital HM Puerta del Sur, Móstoles, Spain) to discuss the recent trial investigating focused ultrasound subthalamotomy and it’s role in the management of Parkinson’s Disease. The abstract entitled: ‘Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!